Plecanatide improves abdominal bloating and bowel symptoms of irritable bowel syndrome with constipation 

Brenner DM, et al. Dig Dis Sci. 2024

Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: post hoc analyses of placebo-controlled trials in adults with severe constipation

Cash BD, et al. Neurogastroenterol Motil. 2023

Plecanatide improves symptoms of irritable bowel syndrome with constipation: results of an integrated efficacy and safety analysis of two phase 3 trials

Brenner DM, et al. Int J Gen Med. 2023

Best practices for the management of chronic idiopathic constipation and irritable bowel syndrome with constipation: a roundtable discussion and review 

Brenner DM. American Journal of Gastroenterology [Supplement]. 2022.

Real-world treatment strategies to improve outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Brenner DM, et al. American Journal of Gastroenterology [Supplement]. 2022.

Burden of constipation: looking beyond bowel movements 

Harris LA, et al. American Journal of Gastroenterology [Supplement]. 2022.

Effective communication strategies and tools for improving treatment outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Kassebaum-Ladewski A, et al. American Journal of Gastroenterology [Supplement]. 2022

Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation 

Sayuk GS, et al. American Journal of Gastroenterology [Supplement]. 2022.

The effect of acid suppression therapy on the safety and efficacy of plecanatide: analysis of randomized phase III trials 

Moshiree B, et al. Clinical Therapeutics. 2022.

Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders 

Sharma A, et al. Alimentary Pharmacology & Therapeutics. 2021.

Diagnosing constipation spectrum disorders in a primary care setting 

Heidelbaugh J, et al. Journal of Clinical Medicine. 2021.

Evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in patients 65 years or older

Menees SB, et al. Clinical Therapeutics. 2020.

Blunted evoked prouroguanylin endocrine secretion in chronic constipation

Waldman SA, et al. Clinical and Translational Gastroenterology. 2019.

Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation

Barish CF, et al. Current Medical Research and Opinion. 2019.

Comment on meta analysis by Shah et al

Griffin PH. American Journal of Gastroenterology. 2018.

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

Waldman SA, et al. Gut. 2018.

Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire

Quigley EMM, et al. Advances in Therapy. 2018.

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

Brenner DM, et al. American Journal of Gastroenterology. 2018.

Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog

Brancale A, et al. Pharmacology Research & Perspectives. 2017.

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses

Shailubhai K, et al. Digestive Diseases and Sciences. 2013.